Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: sitagliptin 100 mg and metformin 2000 mg.
This medication is generally taken twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually.
The starting dose of this medication should be determined according to the patient's current treatment regimen.
1. Patients not currently treated with metformin:
For patients with no prior experience with antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the starting dose is 1 tablet of this medication 50/500 mg twice daily. The dose may be increased to 1 tablet of this medication 50/1000 mg twice daily.
Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication (see Precautions for Use, 2. Patients Who Must Not Receive This Medication).
2. Patients receiving metformin:
- For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended starting dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose.
- Patients switching to this medication from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin.
3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione:
The starting dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg); the starting dose of metformin should take into account the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions).
No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral glucose-lowering medication to this medication. Any change in the treatment regimen for type 2 diabetes may cause a change in glycemic control; therefore, caution and appropriate monitoring are required.
Patients with renal impairment
This medication may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who have no other symptoms that may increase the risk of lactic acidosis, with the following dose adjustment.
Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months.
If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication must be discontinued immediately.
Patients with hepatic impairment
This medication must not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Receive This Medication).
Improvement of glycemic control in patients with type 2 diabetes mellitus
View approved original textHide original text
This medication is used to help patients with type 2 diabetes control their blood sugar levels. Taking it alongside meal and exercise therapies can more effectively manage blood sugar. Sitagliptin and metformin work together to help stabilize blood sugar levels. This also contributes to the prevention of diabetes complications. Therefore, this medication is used to improve blood sugar control.
How to take
Adult dose
For antidiabetic therapy, the dose of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: sitagliptin 100 mg and metformin 2000 mg.
This medication is generally taken twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually.
The starting dose of this medication should be determined according to the patient's current treatment regimen.
1. Patients not currently treated with metformin:
For patients with no prior experience with antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the starting dose is 1 tablet of this medication 50/500 mg twice daily. The dose may be increased to 1 tablet of this medication 50/1000 mg twice daily.
Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication (see Precautions for Use, 2. Patients Who Must Not Receive This Medication).
2. Patients receiving metformin:
- For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended starting dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose.
- Patients switching to this medication from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin.
3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione:
The starting dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg); the starting dose of metformin should take into account the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions).
No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral glucose-lowering medication to this medication. Any change in the treatment regimen for type 2 diabetes may cause a change in glycemic control; therefore, caution and appropriate monitoring are required.
Patients with renal impairment
This medication may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who have no other symptoms that may increase the risk of lactic acidosis, with the following dose adjustment.
Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months.
If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication must be discontinued immediately.
Patients with hepatic impairment
This medication must not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Receive This Medication).
Precautions
This medication contains sitagliptin and metformin, which are used in the treatment of diabetes.
Firstly, severe allergic reactions may occur during the use of this medication, so if symptoms such as skin rash, hives, or difficulty breathing occur, discontinue use immediately and consult a doctor.
Additionally, acute pancreatitis, an inflammation of the pancreas, may occur, so if symptoms such as abdominal pain, nausea, or vomiting arise, inform healthcare professionals immediately.
This medication should not be administered to patients with poor kidney function or those with acute heart failure, myocardial infarction, or severe infections, especially as the risk of lactic acidosis, a serious side effect, increases in patients with impaired kidney function.
Lactic acidosis is a rare complication that occurs when excess lactic acid accumulates in the body, which may present symptoms such as muscle pain, weakness, difficulty breathing, abdominal pain, or decreased consciousness; such symptoms require immediate hospital attention.
During the use of this medication, regular kidney function and blood tests should be conducted to check for abnormalities, especially in the elderly or those with low kidney function.
Furthermore, this medication may cause hypoglycemia, so caution should be exercised when skipping meals or engaging in vigorous exercise, and when combined with other hypoglycemic agents, the risk of hypoglycemia may increase.
Patients scheduled for surgery should discontinue this medication 48 hours prior to the surgery and can resume after kidney function has normalized post-surgery.
It is safer for pregnant women or those who may become pregnant, as well as breastfeeding mothers, to avoid this medication.
Additionally, excessive alcohol consumption should be avoided while taking this medication as it may increase the risk of lactic acidosis.
Other medications may interact with this medication, so be sure to inform healthcare professionals of any currently taken medications.
Finally, it is important to consult with healthcare professionals immediately if you experience any abnormal symptoms or discomfort during the use of this medication to receive appropriate measures.
Side effects
Anaphylaxis
angioedema
Stevens-Johnson syndrome
acute pancreatitis
lactic acidosis
hypoglycemia
diarrhea
upper respiratory infection
headache
nausea
Show 26 moreCollapse
vomiting
abdominal pain
nasopharyngitis
constipation
severe and debilitating arthralgia
bullous pemphigoid
myalgia
limb pain
back pain
interstitial lung disease
pruritus
thrombocytopenia
rhabdomyolysis
dermatitis
loss of appetite
weight loss
decreased appetite
gastrointestinal disorders
itching
dizziness
dyspnea
unstable angina
dizziness
acute renal failure
hypoglycemia
severe arthralgia
Not everyone experiences these, and they can vary from person to person.
Storage
This medication should be stored in a sealed container to prevent air exposure, ideally at room temperature between 1 and 30 degrees Celsius. This will help maintain its effectiveness and prevent deterioration.
Appearance and packaging
Appearance
Bright pink oval film-coated tablet
Package unit
60 tablets/box [10 tablets/PTP x 6]
Same-ingredient medicines
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.